Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2024-11-18 00:00:00 ET · period of report 2024-11-18 · accession 0000950170-24-128202 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-11-18 | 2024-11-18 | ANTX | Easom Eric | CEO, Dir | P - Purchase | $1.00 | +50.0K | 1.07M | +5% | +$50.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-18 | P | A | 50,000 | $1.00 | 1,065,766 | I See Footnote | — | — | (F1) Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019. |